Figure 5. Heatmaps displaying regression slopes of cytokine profiles for BRAF inhibitors.
(A) Heat maps based on regression slopes for HCT-116, HT-29, and KM12C after 48-hour treatment of increasing doses of Regorafenib or (B) Vemurafenib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.